

Real Imaging Receives CE Mark for Real Imager 8 Breast Cancer Screening Exam

Airport City, Israel., May 21, 2014 – Real Imaging Ltd. today announced that it has received CE Mark designation for its Real Imager 8 device intended for use as adjunct breast cancer screening modality. Real Imaging is the first company to introduce an imaging-based risk assessment system that utilizes 3D functional non-invasive metabolic imaging of the breast. The device objectively assesses the risk and likelihood that the woman harbors a breast cancer by assessing several imaging biomarkers associated with malignancy.

“I am very pleased that we have achieved this important milestone for Real Imaging. We developed the Metabolic Imaging and Risk Assessment (MIRA™) technology to address limitation of mammography, particularly for women with dense breast tissue,” said Maiki Yoeli, CEO of Real Imaging. “Our presentation at the recent RSNA meeting gains much interest and was featured by the RSNA Bulletin. There is an unmet need for imaging modalities to complement mammography and provide the radiologist more information to help facilitate a better clinical workup for the woman. The CE Mark would expedite our go-to-market and will enable us to conduct studies in other territories such as Asia-Pacific. We are committed to assisting physicians and medical authorities to increase cancer detection rate, while providing women a comfort, non-radiating, non-invasive and a better experience during their breast exam.”

The Real Imager 8 utilizes the MIRA™ technology to generate the vascular map of the breast non-invasively. Cancerous tumors generate blood vessels and a unique environment such that they can grow silently in the human body with no interruption. The changes in blood vessel maps are detected by the device and using a sophisticated risk model, a suspicion for cancer likelihood is provided. “The device operates by assessing several imaging biomarkers. One can view this as a very novel blood test, however, instead of testing metabolites, protein residues or autoantibodies in the blood stream, imaging biomarkers are assessed for malignancy” added Dr. David Izhaky, VP Research and Development. “We are now teaming with Karolinska Institute to enable a risk-based screening program that will ultimately shape the way women are undergoing breast cancer screening. Other clinical trials will be launched soon in the US, Hong Kong and China.”

About Real Imaging Ltd.

Real Imaging Ltd, an Israel-based company was founded by Boaz Arnon following the death of his mother from breast cancer. The patented technology is based on novel electro-optics and image acquisition modality including a series of proprietary algorithms for cancer detection. The imaging device has no radiation, no compression, very comfort to the woman, does not require any image reading and is suitable to all women including women with dense breast tissue. For more information visit <http://www.realimaging.com>